Use of latent class analysis and patient reported outcome measures to identify distinct long COVID phenotypes: A longitudinal cohort study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 02 02 2023
accepted: 18 05 2023
medline: 5 6 2023
pubmed: 2 6 2023
entrez: 2 6 2023
Statut: epublish

Résumé

We sought to 1) identify long COVID phenotypes based on patient reported outcome measures (PROMs) and 2) determine whether the phenotypes were associated with quality of life (QoL) and/or lung function. This was a longitudinal cohort study of hospitalized and non-hospitalized patients from March 2020 to January 2022 that was conducted across 4 Post-COVID Recovery Clinics in British Columbia, Canada. Latent class analysis was used to identify long COVID phenotypes using baseline PROMs (fatigue, dyspnea, cough, anxiety, depression, and post-traumatic stress disorder). We then explored the association between the phenotypes and QoL (using the EuroQoL 5 dimensions visual analogue scale [EQ5D VAS]) and lung function (using the diffusing capacity of the lung for carbon monoxide [DLCO]). There were 1,344 patients enrolled in the study (mean age 51 ±15 years; 780 [58%] were females; 769 (57%) were of a non-White race). Three distinct long COVID phenotypes were identified: Class 1) fatigue and dyspnea, Class 2) anxiety and depression, and Class 3) fatigue, dyspnea, anxiety, and depression. Class 3 had a significantly lower EQ5D VAS at 3 (50±19) and 6 months (54 ± 22) compared to Classes 1 and 2 (p<0.001). The EQ5D VAS significantly improved between 3 and 6 months for Class 1 (median difference of 6.0 [95% CI, 4.0 to 8.0]) and Class 3 (median difference of 5.0 [95% CI, 0 to 8.5]). There were no differences in DLCO between the classes. There were 3 distinct long COVID phenotypes with different outcomes in QoL between 3 and 6 months after symptom onset. These phenotypes suggest that long COVID is a heterogeneous condition with distinct subpopulations who may have different outcomes and warrant tailored therapeutic approaches.

Identifiants

pubmed: 37267379
doi: 10.1371/journal.pone.0286588
pii: PONE-D-23-03084
pmc: PMC10237387
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0286588

Subventions

Organisme : CIHR
ID : HEC 181075
Pays : Canada

Informations de copyright

Copyright: © 2023 Wong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Respir Med. 2006 Oct;100(10):1767-74
pubmed: 16531031
Thorax. 2021 Jan;76(1):37-43
pubmed: 33023996
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049743
pubmed: 34697975
Sleep. 2008 Nov;31(11):1601-7
pubmed: 19014080
J Gen Intern Med. 2016 Oct;31(10):1206-11
pubmed: 27170304
ERJ Open Res. 2021 Sep 13;7(3):
pubmed: 34522693
Open Forum Infect Dis. 2022 Mar 07;9(4):ofac060
pubmed: 35265728
Respir Care. 2015 Jan;60(1):88-95
pubmed: 25336531
Eur Respir J. 2020 Jun 18;55(6):
pubmed: 32381497
PLoS One. 2022 Sep 29;17(9):e0275274
pubmed: 36174032
Spine J. 2007 Sep-Oct;7(5):541-6
pubmed: 17448732
Ann Am Thorac Soc. 2021 Jul;18(7):1253-1255
pubmed: 33472019
Chest. 2002 Jul;122(1):197-201
pubmed: 12114358
JAMA Netw Open. 2021 May 3;4(5):e2111417
pubmed: 34037731
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
EBioMedicine. 2023 Jan;87:104413
pubmed: 36563487
Eur Respir J. 2020 Nov 26;56(5):
pubmed: 33008936
Thorax. 2021 Apr;76(4):402-404
pubmed: 33273023
Crit Care Med. 2021 Jan 1;49(1):e63-e79
pubmed: 33165028
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617
PLoS Biol. 2015 Jan 06;13(1):e1002033
pubmed: 25562316
J Cardiopulm Rehabil. 2005 Nov-Dec;25(6):370-7
pubmed: 16327533
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Lancet Respir Med. 2021 Nov;9(11):1275-1287
pubmed: 34627560

Auteurs

Alyson W Wong (AW)

Department of Medicine, University of British Columbia, Vancouver, Canada.
Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

Karen C Tran (KC)

Division of General Internal Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Mawuena Binka (M)

Data and Analytic Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.
School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.

Naveed Z Janjua (NZ)

Data and Analytic Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.
School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.

Hind Sbihi (H)

Data and Analytic Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.
School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.

James A Russell (JA)

Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

Christopher Carlsten (C)

Department of Medicine, University of British Columbia, Vancouver, Canada.
School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.

Adeera Levin (A)

Department of Medicine, University of British Columbia, Vancouver, Canada.

Christopher J Ryerson (CJ)

Department of Medicine, University of British Columbia, Vancouver, Canada.
Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH